Mendiratta Prateek, Febbo Phillip G
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA.
Mol Diagn Ther. 2007;11(6):345-54. doi: 10.1007/BF03256258.
Prostate cancer remains a common cause of cancer death in men. Applications of new genomic technologies to the recent development of high-quality prostate cancer models in multiple contexts have added great molecular insight into the development of and progression to metastasis. Genomic analysis of DNA, RNA, and protein alterations allows for the global assessment of this disease and provides the molecular framework to improve risk classification, outcome prediction, and development of targeted therapies. The creation of expression profiles and signatures will allow the evaluation of cancer phenotypes and give insight into determining those with increased risk of cancer, identification of critical pathways involved in the development of cancer, prediction of disease outcome, and assessment of the response of cancer to established and novel therapies. This review focuses on highlighting recent work in genomics and on its role in evaluating potential genetic modifiers of prostate cancer and novel biomarkers that may help with prostate cancer diagnosis, its potential to provide a better understanding of prostate cancer behavior and transition to metastatic disease, and its role in current and new therapies in prostate cancer. This framework has the exciting potential to be predictive and provide personalized and individual treatment to the large number of men diagnosed with prostate cancer each year.
前列腺癌仍然是男性癌症死亡的常见原因。新基因组技术在多种情况下应用于高质量前列腺癌模型的最新进展，为转移的发生和发展增添了深入的分子见解。对DNA、RNA和蛋白质改变进行基因组分析，有助于对这种疾病进行全面评估，并为改善风险分类、结果预测和开发靶向治疗提供分子框架。创建表达谱和特征将有助于评估癌症表型，并深入了解确定癌症风险增加者、识别癌症发生过程中涉及的关键途径、预测疾病结果以及评估癌症对现有和新型疗法的反应。本综述重点介绍基因组学的最新研究工作及其在评估前列腺癌潜在遗传修饰因子和新型生物标志物方面的作用，这些生物标志物可能有助于前列腺癌的诊断，有助于更好地理解前列腺癌的行为及其向转移性疾病的转变，以及在前列腺癌现有和新疗法中的作用。这个框架具有令人兴奋的潜力，能够进行预测，并为每年大量被诊断为前列腺癌的男性提供个性化治疗。
